Coherus BioSciences Inc (CHRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $81.21M
Last updated: Nov 17, 2026 at 4:38 PM ET
Coherus BioSciences Inc (CHRS) Statistics
Coherus BioSciences (CHRS) has a market cap of $81.21M and an enterprise value of $80.27M. It kept -253.43% of revenue as net income over the last 12 months. Its share count is up 33.33% from a year earlier.
Total Valuation
Enterprise value is 1.15% below the market cap, as cash exceeds debt.
| Market Cap | $81.21M |
|---|---|
| Enterprise Value | $80.27M |
| Latest price (Nov 17, 2026) | $0.48 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.4x and 2.9x. Its year-end P/S ranged from 1.2x to 153.9x from 2016 to 2025.
| P/S Ratio | 1.4x |
|---|---|
| Forward P/S | 1.4x |
| P/B Ratio | 2.9x |
Price Statistics
The stock is down 59.79% over 52 weeks and trades 52.94% below its 50-day average.
| Beta (1Y) | 2.05 |
|---|---|
| 52-Week Change | -59.79% |
| 1-Month Change | -50.09% |
| 3-Month Change | -64.02% |
| 6-Month Change | -67.67% |
| 5-Year Change | -95.04% |
| 10-Year Change | -96.96% |
| Total Return (1Y) | -59.79% |
| Total Return (3Y CAGR) | -39.20% |
| Total Return (5Y CAGR) | -51.89% |
| Max Drawdown (1Y) | -80.94% |
| Max Drawdown (3Y) | -85.63% |
| Sharpe Ratio (1Y) | -1.06 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $1.02 |
| 200-Day Average | $1.45 |
| 52-Week Range | $0.48 to $2.62 |
| RSI (14 Days) | 26.8 |
| Average Volume (20 Days) | 2.56M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.51x current liabilities, and total debt is 2.08x shareholder equity.
| Current Ratio | 1.51x |
|---|---|
| Quick Ratio | 1.45x |
| Debt / Equity | 2.08x |
| Interest Coverage | -11.05x |
Returns and Efficiency
Return on invested capital is -144.80% and return on equity is -538.38% over the last 12 months.
| Return on Equity (ROE) | -538.38% |
|---|---|
| Return on Assets (ROA) | -79.45% |
| Return on Invested Capital (ROIC) | -144.80% |
| Return on Capital Employed (ROCE) | -149.37% |
| ROA (5Y Average) | -13.87% |
| Asset Turnover | 0.16x |
| Inventory Turnover | 3.09x |
| Receivables Turnover | 3.89x |
| Cash Conversion Cycle | -100 days |
Scores
CHRS has an Altman Z-Score of -13.98, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -13.98 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $53.64M over the last 12 months is up 44.36% from the 12 months before.
| Revenue | $53.64M |
|---|---|
| Revenue Growth (YoY) | +44.36% |
| Gross Profit | $37.45M |
| Operating Income | -$148.01M |
| Pretax Income | -$155.50M |
| Net Income | -$135.94M |
| EBITDA | -$139.11M |
| EBIT | -$142.60M |
| Reported EPS (TTM) | -$1.06 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 14.76% of the $171.10M in total assets.
| Cash and Equivalents | $53.49M |
|---|---|
| Total Debt | $52.55M |
| Net Cash | $936.00K |
| Net Cash Per Share | $0.01 |
| Working Capital | $38.49M |
| Shareholder Equity | $25.25M |
| Book Value Per Share | $0.16 |
| Tangible Book Value | -$19.11M |
| Total Assets | $171.10M |
| Total Liabilities | $145.85M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$173.71M |
|---|---|
| FCF Per Share | -$1.12 |
| Depreciation and Amortization | $3.49M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -275.94%.
| Gross Margin | 69.81% |
|---|---|
| Operating Margin | -275.94% |
| Pretax Margin | -289.91% |
| Net Margin | -253.43% |
| EBITDA Margin | -259.34% |
| EBIT Margin | -265.86% |
| Gross Margin (5Y Average) | 64.30% |
| Net Margin (5Y Average) | 37.56% |
Growth
Revenue fell 41.54% a year over 3 years.
| Revenue Growth (3Y CAGR) | -41.54% |
|---|---|
| Revenue Growth (5Y CAGR) | -38.41% |
Dividends and Yields
CHRS does not pay a dividend.
| Buyback Yield | -83.49% |
|---|---|
| Shareholder Yield | -83.49% |
Peer Position
Against 8 similar companies, CHRS has the 6th highest P/S.
P/S RatioPeer median 4.4x
ROICPeer median -8.39%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.65%
| P/S Ratio | 1.4x vs 4.4x median |
|---|---|
| ROIC | -144.80% vs -8.39% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +44.36% vs +6.65% median |
Analyst Forecast
Consensus estimates put revenue growth at 48.42% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +48.42% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CHRS
What is CHRS's market cap?
Coherus BioSciences has a market cap of $81.21M. Its enterprise value, which adds debt and subtracts cash, is $80.27M.
How many shares of CHRS are outstanding?
Coherus BioSciences has 154.97M shares outstanding. The count is up 33.33% from a year earlier.
Does CHRS pay a dividend?
No. Coherus BioSciences does not pay a dividend.
How much debt does CHRS have?
Coherus BioSciences has $52.55M of total debt and $53.49M of cash and equivalents, a net cash position of $936.00K.
CHRS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors